Effects of man made pollutants on an ecosystem are initiated at the cellular level where a prime determinant for survival of an organism is its ability to metabolise and excrete toxic chemicals or their metabolites, thereby preventing cellular toxicity or damage to germ cell DNA. Cytochrome P450 (CYP) enzymes are responsible (in concert with the remainder of the Ah battery enzymes) for the metabolism of numerous xenobiotics and endogenous compounds, including the metabolic activation of most environmental toxic chemicals and carcinogens. Genetic polymorphisms which affect performance of these enzymatic detoxification systems may alter tolerance to pollutants and thus survival in polluted environments. Alterations in the susceptibility of individuals and the development of resistant populations has arisen by forced selection of populations with variant genes, resulting in increased detoxification capacity. There is evidence for such scenarios of variations in activities of pollutant biotransforming enzymes of fish contributing to survival in polluted estuarine environments and several chemically resistant populations have been identified in the USA and Europe. In fish it has been demonstrated that CYP1A enzyme activity is required to activate some carcinogenic xenobiotics to a metabolic state in which they can form DNA adducts. The mechanism of reduced CYP1A expression in highly contaminated populations may therefore represent resistance to chemical stressors. European flounder (Platichthys flesus) from some waterways which have a long history of severe sedimentary contamination do not show elevated levels of CYP1A. The aim of the current study was to investigate whether any heritable differences were apparent between offspring from parents inhabiting long-term polluted and pristine areas. Flounder were obtained from a highly polluted estuary in the UK and crossed with fish from a relatively pristine environment. Offspring were raised in communal tanks in order to standardise environmental conditions, and allow investigations into the genetic variation of CYP1A. To allow identification of offspring to parental fish, polymorphic microsatellite loci were isolated and characterised for the flounder. Novel cDNA probes to transcription factors in the detoxification pathway (AhR2 and ARNT2) were cloned for flounder, and RT-PCR / Southern blot methods were developed for quantitation of gene transcript levels. A novel method of CYP1A quantification using real-time PCR was developed. PAH and PCB exposure trials were carried out on mixed batch offspring, and CYP1A gene transcript levels assessed using Northern blot and real-time PCR techniques. Offspring were genotyped to their parents using the microsatellites obtained, and CYP1A transcript levels were correlated with clean and polluted areas. CYP1A was further correlated to transcription factor expression, and data are presented. Following exposure to the commercial PCB mixture, Aroclor 1254, CYP1A transcript levels were found to be significantly lower in families whose parents originated from a polluted area. This observation indicates that there is a possible genetic component to variation in CYP1A levels, and that these fish may have acquired a heritable tolerance to polluted areas. The lack of induction, or correlation with CYP1A levels, of AhR2 and ARNT2 expression indicates a possible AhR independent pathway for the metabolism of PCBs in the flounder. © Tom Dixon 2003 http://www.tomdixon.org

Introduction: L'étude des biomarqueurs a le potentiel de documenter sur les mécanismes sous-jacents de l'étiologie du cancer du poumon. Dans cette étude, nous avons étudié l’association entre la méthylation de l’ADN dans les gènes F2RL3 et AHRR et le cancer du poumon. Méthodes: Une étude cas-témoin avec échantillonnage cumulatif a été nichée dans la cohorte CARTaGENE. Les cas (N=187) se composent de tous les participants diagnostiqués avec un cancer du poumon incident entre le début de la cohorte (2009) et 2015 et qui avaient fourni un échantillon de sang; les témoins (N=378) ont été échantillonnés à la fin du suivi parmi les non-malades selon un appariement fréquentiel (2:1) pour l'âge, le sexe et le moment du prélèvement sanguin. Sequenom EpiTYPER® a été utilisé pour quantifier les niveaux de méthylation dans sept et 33 sites CpG de F2RL3 et AHRR, respectivement. Les rapports de méthylation de l'ADN sur tous les sites CpG individuels et en tant que mesure moyenne ont été paramétrés à la fois comme variables continues et catégorielles. Une régression logistique multivariable non conditionnelle a été utilisée pour estimer les rapports de cotes (OR) et les intervalles de confiance (IC) à 95 % de l’association entre la méthylation de F2RL3 et AHRR et le cancer du poumon tout en contrôlant les facteurs de confusion identifiés à l'aide de graphiques acycliques dirigés. Résultats: Une forte association inverse entre les niveaux moyens de méthylation de l'ADN et le cancer du poumon a été observée pour F2RL3 (OR par écart type (SD) de changement de méthylation = 0,65, IC à 95 %: 0,53-0,80) et AHRR (OR par SD de changement de méthylation = 0,66, IC à 95 %: 0,53 à 0,80). De même, les sites CpG individuels ont montré des ORs (par SD de changement de méthylation) allant de 0,61 à 0,70 pour six des sept sites CpG de F2RL3 et de 0,57 à 0,79 pour 17 des 33 sites CpG de AHRR. Les sites CpG restants de F2RL3 et AHRR n'ont montré aucune association avec le risque de cancer du poumon, à l'exception d'un site CpG dans AHRR (chr5:369774) qui avait un OR de 1,25 (IC à 95 %: 1,02-1,54). Conclusion : Ces résultats confirment le rôle des mécanismes épigénétiques dans l'étiologie du cancer du poumon. / Background: The study of biomarkers has the potential to inform on underlying mechanisms in lung cancer etiology. In this study, we investigated DNA methylation in the F2RL3 and AHRR genes, and lung cancer risk. Methods: A case-control study with cumulative sampling was nested in the CARTaGENE cohort. Cases (N=187) consisted of all participants diagnosed with incident lung cancer from baseline to 2015 and who had provided a blood sample; controls (N=378) were sampled at a ratio of 2:1 with frequency-matching by age, sex, and timing of blood sampling. Sequenom EpiTYPER® was used to quantify methylation levels in seven and 33 CpG sites of F2RL3 and AHRR, respectively. DNA methylation ratios across all individual CpG sites and as an average measure were parametrized both as continuous and categorical variables. Unconditional multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CI) for lung cancer associated with F2RL3 and AHRR methylation while controlling for confounders identified using directed acyclic graphs. Results: A strong inverse relationship between average DNA methylation levels and lung cancer was observed for both F2RL3 (OR per standard deviation (s.d.) in methylation change = 0.65, 95% CI: 0.53-0.80) and AHRR (OR per s.d. in methylation change = 0.66, 95% CI: 0.53-0.80). Similarly, ORs for individual CpG sites (per s.d. in methylation change) ranged from 0.61-0.70 for six out of the seven CpG sites of F2RL3 and from 0.57-0.79 for 17 out of 33 CpG sites of AHRR. The methylation levels of the remaining CpG sites within F2RL3 and AHRR were not associated with lung cancer risk, except for one CpG site within AHRR (chr5:369774) which had an OR of 1.25 (95% CI: 1.02-1.54). Conclusion: These findings support the role of epigenetic mechanisms in lung cancer etiology.